Jose Avila Ornelas
Neurology · Caguas, PRNPI 1467868927
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $422,362 of the $537,738 with a category attached, or 78.5%. 21 manufacturers reported payments, led by Biogen at 38.7% of the total. Among neurology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,112 payments — averaging $483.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$208K
- EMD Serono, Inc.$96K
- AstraZeneca$86K
- Amgen$63K
- Novartis$43K
- Genentech USA, Inc.$28K
- plus $15K from 15 others
Across 7 payments — averaging $46,428 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$256K
- E.r. Squibb & Sons, L.L.C.$43K
- Bristol Myers Squibb$21K
- AstraZeneca$6K
What the payments were for
- Consulting fees$55,99910%
- Speaking & faculty fees$422,36279%
- Travel & lodging$29,3155%
- Food & beverage$29,9366%
- Education$1260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 287 | $208,212 |
| EMD Serono, Inc. | 119 | $96,254 |
| AstraZeneca | 111 | $85,670 |
| Amgen(2 entities) | 71 | $62,564 |
| Novartis | 216 | $42,667 |
| Genentech USA, Inc. | 67 | $27,540 |
| Banner Life Sciences, LLC | 23 | $3,786 |
| E.r. Squibb & Sons, L.L.C. | 81 | $3,578 |
| Genentech, Inc. | 4 | $2,101 |
| Johnson & Johnson | 27 | $1,566 |
| Sanofi | 41 | $1,355 |
| TG Therapeutics, Inc. | 13 | $917 |
| AbbVie | 18 | $472 |
| UCB, Inc. | 4 | $283 |
| Eli Lilly Export S.A. Puerto Rico Branch | 10 | $231 |
| ANI Pharmaceuticals, Inc. | 7 | $187 |
| Mallinckrodt Enterprises LLC | 5 | $143 |
| Teva Pharmaceuticals USA, Inc. | 4 | $136 |
| Vanda Pharmaceuticals Inc. | 2 | $35 |
| Bristol Myers Squibb | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$537,738 in reported general payments places this provider in the 95th percentile of 129 neurology providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 90 | $808,275 |
| VumerityDiroximel Fumarate | 59 | $522,269 |
| EnspryngSatralizumab-Mwge | 24 | $413,679 |
| MayzentSiponimod | 36 | $349,406 |
| BafiertamMonomethyl Fumarate | 20 | $133,740 |
| AubagioTeriflunomide | 12 | $113,392 |
| Emgality PenGalcanezumab-Gnlm | 41 | $30,658 |
| Emgality SyringeGalcanezumab-Gnlm | 23 | $16,136 |
| Dalfampridine ErDalfampridine | 40 | $2,776 |
| Baclofen | 70 | $1,068 |
| Pregabalin | 29 | $902 |
| Mycophenolate Mofetil | 16 | $811 |
| Gabapentin | 57 | $592 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $470 |
| Carbamazepine | 27 | $379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $208,212 | $522,26959 claims |
| Genentech USA, Inc.Enspryng | $27,540 | $413,67924 claims |
| NovartisMayzent | $42,667 | $349,40636 claims |
| SanofiAubagio | $1,355 | $113,39212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 129 neurology providers in Puerto Rico.
Other neurology in Caguas
- Patricia de JesusCaguas$310K
- Karen Nater PineiroCaguas$7K
- Luis ForastieriCaguas$6K
- Naggai Gonzalez SegarraCaguas$4K
- Daniel Reyes de JesusCaguas$3K
- Ulises NoboCaguas$2K
- Angel ChineaGuaynabo$1.7M
- Franchesca Fiorito-TorresSan Juan$453K
- Mari GarciaSan Juan$138K
- Cristina Cabret-AymatSan Juan$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.